Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-TOX versus EOX for advanced or metastatic gastric cancer
2011-005537-39Phase 3Terminated
- Sponsor
- Fondazione Giscad per la Ricerca sui Tumori
- Start
- Jul 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, oxaliplatin, capecitabine and epirubicin in gastric adenocarcinoma and gastric cancer (GC) (2 arms), sponsored by Fondazione Giscad per la Ricerca sui Tumori. Primary endpoint: Overall survival. Started Jul 2012; status: terminated.
02
Drugs
docetaxeloxaliplatincapecitabineepirubicin
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2011-005537-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005537-39.